Aeterna discontinues vaccine development; Idera rebrands as Aceragen
As biotechs start to detail 2023 plans — M&A, new emphases in drug R&D and more with investors — others are starting to trim back or using the new year as an opportunity to do an about-face and try and start with a clean slate.
Three such biotechs unveiled next steps for their respective companies Tuesday morning.
Aeterna axes early-stage vaccine pipeline after reacquiring regional rights to sole product
Aeterna Zentaris is cutting its work on a vaccine platform, which the biotech said had potential applications against chlamydia and Covid-19. However, the company said it had not been able to select a clinical development candidate for a Covid-19 vaccine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.